A Phase 1 interventional study of Modufolin (arfolitixorin) in Phase I Study in Healthy Volunteers to Evaluate ECG Effect, sponsored by Isofol Medical AB. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Isofol Medical AB · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluating ECG effects, safety, tolerability and pharmacokinetics of single ascending dose of Modufolin® in healthy male volunteers
An adaptive randomised, double-blind, single-centre, placebo-controlled Phase I study evaluating ECG effects, safety, tolerability and PK of single ascending doses of Modufolin® for Injection, 100 mg in healthy male volunteers. Thirty-three (33) eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort. Within each cohort, subjects will be randomised to receive either placebo (3 subjects) or Modufolin® for Injection, 100 mg (8 subjects). There will be 3 pre-defined ascending dose-levels. Additional dose levels may be considered if recommended by the internal Safety Review cCommittee. There will be an interval between each dose level to allow time for safety data to be analyzed and evaluated by the iSRC. The iSRC will have the choice to decide to escalate the dose as planned, reduce or increase the dose escalation step, repeat the dose, reduce the dose or terminate the study. The total study duration for the subjects will be approximately 5 weeks and there will be in total 3 visits to the clinic. Subjects will be screened for eligibility according to study-specific inclusion/exclusion criteria within 4 weeks prior to start of stud treatment (Visit 1; Screening visit). The subjects will be confined to the research clinic from the evening before dosing (Day -1) until 24 hrs post dose (Days 1 and 2). The subjects should be fasting overnight (8 hrs) before IMP/placebo administration until 4 hrs post-dose. A Follow-up Visit will be performed 5 to 10 days after dose administration of for each cohort.
Isofol Medical AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or subject´s ability to participate in the study.
Pulse \< 40 or > 85 beats per min 6. Prolonged (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting at the time of screening, as judged by the Investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
Drug: Modufolin (arfolitixorin)
Three cohorts, 3 subjects will be randomised to placebo
Drug: Modufolin (arfolitixorin)
Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
Also known as: arfolitixorin
Change-from-baseline QTcF (ΔQTcF)
At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings. The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Relationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations
Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.
Time frame: 5 minute post-dose time point
Change-from-baseline Heart Rate (ΔHR)
The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Change-from-baseline PR (ΔPR)
The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Change-from-baseline QRS (ΔQRS)
The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Number of Participants With Categorical QTcF Outliers
QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Categorical Outliers for HR, PR Interval, QRS Interval
Categorical Analysis of outliers for HR, PR, and QRS intervals
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Categorical Analysis for T Wave Morphology
Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.
Time frame: Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.
Physical Examination
A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).
Time frame: At visit 1 (screening) and follow-up
Systolic Blood Pressure
Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
Time frame: Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).
Diastolic Blood Pressure
Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.
Time frame: Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).
Vital Signs: Pulse
Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.
Time frame: Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).
Safety Laboratory Measurements
The following safety laboratory parameters were assessed: Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.
Time frame: Pre-dose at screening (visit 1) and -2h (visit 2). Post-dose at following timepoints: 24 h (visit 2) and at follow-up (visit 3)
Frequency, Seriousness and Intensity of AEs
An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment
Time frame: From start of IMP administration to follow-up visit
Plasma PK Characteristics: C0
The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h. pre-dose to 24 h post-dose
Plasma PK Characteristics: C5min
Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h
Plasma PK Characteristics: AUClast
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: AUClast/Dose
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: t1/2
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: CL
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: Vss
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h
Plasma PK Characteristics: Cmax
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: Tmax
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.
Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.
Time frame: Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h
Number of Subjects With AEs
An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment
Time frame: From start of IMP administration to follow-up visit
Subjects were recruited from a database of healthy volunteers at CTC and from advertising in media, including social media.
| Milestone | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 9 |
| Completed | 8 | 8 | 8 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings. The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.
| msec | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| End of infusion | 2.8 ± 2.85 | 9.2 ± 2.84 | 8.5 ± 2.87 | 1.1 ± 2.69 |
| 5 min post-dose | 11.2 ± 2.28 | 9.1 ± 2.28 | 22.4 ± 2.31 | 0.0 ± 2.16 |
| 15 min post-dose | 3.1 ± 1.48 | 7.5 ± 1.47 | 12.4 ± 1.51 | 0.2 ± 1.40 |
| 30 min post-dose | 1.2 ± 1.43 | 2.5 ± 1.42 | 4.2 ± 1.47 | 0.8 ± 1.36 |
| 1 h post-dose | -1.2 ± 1.38 | -0.7 ± 1.38 | -0.9 ± 1.42 | 1.4 ± 1.32 |
| 2 h post-dose | -3.5 ± 1.97 | -1.7 ± 1.96 | 1.0 ± 1.99 | 0.7 ± 1.86 |
| 3 h post-dose | -2.8 ± 2.58 | -0.8 ± 2.58 | 0.9 ± 2.60 | 3.8 ± 2.44 |
| 4 h post-dose | -3.3 ± 2.70 | 0.7 ± 2.70 | 0.0 ± 2.72 | 2.6 ± 2.55 |
| 5 h post-dose | 5.4 ± 3.25 | 2.6 ± 3.37 | 0.8 ± 3.27 | 11.5 ± 3.07 |
| 6 h post-dose | -0.8 ± 2.73 | -2.5 ± 2.72 | -6.7 ± 2.75 | 6.4 ± 2.58 |
| 8 h post-dose | -5.5 ± 2.91 | -5.5 ± 2.90 | -7.7 ± 2.93 | -0.9 ± 2.75 |
| 12 h post-dose | -4.5 ± 2.86 | -6.6 ± 2.86 | -4.1 ± 2.95 | 2.8 ± 2.70 |
| 24 h post-dose | -5.9 ± 2.85 | -8.1 ± 2.84 | -4.6 ± 3.01 | -1.3 ± 2.69 |
Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.
| msec / ng/mL | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® |
|---|---|---|---|
| 5,10-MTHF | 24111.78 (19194.04 to 30289.52) | 51566.94 (46351.78 to 57368.87) | 69012.28 (60609.82 to 78579.59) |
| THF | 15995.29 (13750.28 to 18606.83) | 29386.77 (26812.58 to 32208.09) | 44018.37 (40400.31 to 47960.44) |
| 5-Methyl-THF | 218.18 (176.04 to 270.40) | 544.01 (435.70 to 679.25) | 333.09 (279.56 to 396.86) |
| 5-Formyl-THF | 296.43 (114.76 to 765.71) | 567.17 (414.42 to 776.22) | 379.33 (333.23 to 431.81) |
| ΔΔQTcF | 4.15 (0.97 to 7.33) | 13.25 (9.36 to 17.14) | 19.88 (15.40 to 24.35) |
The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.
| bpm | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| End of infusion | 2.6 ± 1.91 | 2.7 ± 1.91 | 2.0 ± 1.92 | -2.1 ± 1.80 |
| 5 min post-dose | 8.2 ± 2.56 | 7.4 ± 2.55 | 13.3 ± 2.56 | 0.0 ± 2.41 |
| 15 min post-dose | 3.9 ± 1.63 | 3.6 ± 1.63 | 2.6 ± 1.64 | -1.6 ± 1.53 |
| 30 min post-dose | 3.3 ± 2.00 | 1.3 ± 2.00 | 3.0 ± 2.00 | -0.7 ± 1.88 |
| 1 h post-dose | 5.0 ± 1.90 | 0.0 ± 1.90 | -0.9 ± 1.91 | -1.3 ± 1.79 |
| 2 h post-dose | 3.2 ± 1.52 | -0.1 ± 1.52 | -2.6 ± 1.53 | -1.8 ± 1.43 |
| 3 h post-dose | 2.2 ± 1.47 | 0.3 ± 1.46 | 0.3 ± 1.47 | -2.3 ± 1.38 |
| 4 h post-dose | 1.7 ± 1.82 | 2.0 ± 1.82 | 0.2 ± 1.83 | -3.3 ± 1.72 |
| 5 h post-dose | 11.9 ± 2.06 | 12.4 ± 2.12 | 8.9 ± 2.06 | 9.5 ± 1.94 |
| 6 h post-dose | 8.3 ± 2.52 | 12.5 ± 2.52 | 6.2 ± 2.53 | 5.4 ± 2.38 |
| 8 h post-dose | 8.1 ± 2.24 | 8.0 ± 2.23 | 2.5 ± 2.24 | 2.1 ± 2.11 |
| 12 h post-dose | 7.6 ± 2.41 | 5.3 ± 2.41 | 3.6 ± 2.54 | 0.6 ± 2.27 |
| 24 h post-dose | 6.0 ± 2.80 | 5.7 ± 2.80 | 8.0 ± 3.00 | 8.6 ± 2.64 |
The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.
| msec | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| End of infusion | -1.6 ± 2.08 | -4.4 ± 2.08 | -2.1 ± 2.08 | -1.6 ± 1.96 |
| 5 min post-dose | -1.5 ± 2.07 | -4.5 ± 2.07 | -3.1 ± 2.07 | -0.1 ± 1.96 |
| 15 min post-dose | -2.3 ± 2.61 | -1.2 ± 2.61 | 0.2 ± 2.61 | 3.8 ± 2.46 |
| 30 min post-dose | -1.7 ± 2.11 | -3.7 ± 2.11 | 1.3 ± 2.11 | 2.9 ± 1.99 |
| 1 h post-dose | -5.2 ± 1.89 | -3.6 ± 1.89 | -0.3 ± 1.89 | 0.4 ± 1.79 |
| 2 h post-dose | -4.1 ± 2.13 | -4.1 ± 2.13 | 1.1 ± 2.13 | 3.1 ± 2.01 |
| 3 h post-dose | -5.3 ± 2.14 | -4.2 ± 2.14 | -1.6 ± 2.14 | 1.2 ± 2.02 |
| 4 h post-dose | -5.2 ± 1.84 | -4.6 ± 1.84 | -2.1 ± 1.84 | 1.4 ± 1.74 |
| 5 h post-dose | -8.8 ± 2.59 | -7.1 ± 2.71 | -7.8 ± 2.59 | -3.5 ± 2.44 |
| 6 h post-dose | -9.4 ± 2.04 | -8.4 ± 2.04 | -5.8 ± 2.04 | -3.9 ± 1.93 |
| 8 h post-dose | -8.6 ± 2.62 | -7.2 ± 2.62 | -4.3 ± 2.62 | -5.6 ± 2.47 |
| 12 h post-dose | -7.9 ± 3.12 | -1.5 ± 3.12 | -6.9 ± 3.22 | -1.7 ± 2.94 |
| 24 h post-dose | -5.9 ± 2.77 | -5.6 ± 2.77 | -6.4 ± 2.88 | -6.8 ± 2.61 |
The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.
| msec | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| End of infusion | -0.1 ± 0.27 | -0.2 ± 0.27 | -0.1 ± 0.27 | 0.5 ± 0.25 |
| 5 min post-dose | -0.7 ± 0.28 | -0.8 ± 0.28 | -1.2 ± 0.28 | 0.0 ± 0.26 |
| 15 min post-dose | -0.2 ± 0.25 | -0.3 ± 0.25 | -0.1 ± 0.25 | 0.0 ± 0.24 |
| 30 min post-dose | -0.7 ± 0.27 | 0.0 ± 0.27 | -0.5 ± 0.27 | 0.0 ± 0.26 |
| 1 h post-dose | -0.2 ± 0.26 | 0.1 ± 0.26 | 0.2 ± 0.26 | 0.0 ± 0.24 |
| 2 h post-dose | -0.2 ± 0.22 | 0.0 ± 0.22 | -0.1 ± 0.22 | -0.1 ± 0.21 |
| 3 h post-dose | 0.0 ± 0.30 | -0.1 ± 0.31 | -0.4 ± 0.30 | 0.2 ± 0.29 |
| 4 h post-dose | 0.1 ± 0.39 | -0.5 ± 0.39 | 0.2 ± 0.38 | 0.9 ± 0.36 |
| 5 h post-dose | 0.4 ± 0.47 | 0.4 ± 0.49 | 0.1 ± 0.47 | 0.2 ± 0.45 |
| 6 h post-dose | -0.3 ± 0.52 | -0.4 ± 0.52 | -0.8 ± 0.52 | -0.7 ± 0.49 |
| 8 h post-dose | -0.3 ± 0.53 | -0.3 ± 0.53 | -0.5 ± 0.53 | -0.6 ± 0.50 |
| 12 h post-dose | 0.5 ± 0.56 | 0.3 ± 0.56 | -0.6 ± 0.58 | -1.0 ± 0.53 |
| 24 h post-dose | 0.0 ± 0.45 | 0.4 ± 0.45 | -0.9 ± 0.47 | -0.9 ± 0.42 |
QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)
| Participants | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| No. participants with QTcF > 450 and ≤ 480 msec | 0 | 0 | 1 | 0 |
| No. participants with QTcF > 480 and ≤ 500 msec | 0 | 0 | 0 | 0 |
| No. participants with QTcF > 500 msec | 0 | 0 | 0 | 0 |
| No. participants with ΔQTcF of > 30 and ≤ 60 msec | 0 | 0 | 2 | 0 |
| No. participants with ΔQTcF > 60 msec | 0 | 0 | 0 | 0 |
Categorical Analysis of outliers for HR, PR, and QRS intervals
| Participants | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| HR changes >25% decrease from baseline to <50 bpm | 0 | 0 | 0 | 0 |
| HR changes >25% increase from baseline to >100bpm | 0 | 0 | 0 | 0 |
| PR changes > 25% increase from baseline to >200ms | 0 | 0 | 0 | 0 |
| QRS changes > 25% increase from baseline to >120ms | 0 | 0 | 0 | 0 |
Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.
| Participants | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Flat | 0 | 0 | 0 | 0 |
| Notched (+) | 0 | 0 | 0 | 0 |
| Biphasic | 0 | 0 | 0 | 0 |
| Normal (-) | 0 | 0 | 0 | 0 |
| Notched (-) | 0 | 0 | 0 | 0 |
| U wave presence | 0 | 0 | 0 | 0 |
A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).
| Participants | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Abnormal NCS - Visit 1 | 0 | 0 | 1 | 0 |
| Abnormal CS - Visit 1 | 0 | 0 | 0 | 0 |
| Abnormal NCS - Follow-up | 0 | 0 | 0 | 0 |
| Abnormal CS - Follow-up | 0 | 0 | 0 | 0 |
Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
| mmHg | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Screening | 115.50 ± 7.60 | 121.25 ± 7.07 | 116.63 ± 9.56 | 125.56 ± 14.82 |
| Visit 2 Day 1 (-00:15) | 111.38 ± 10.94 | 109.38 ± 9.36 | 117.38 ± 8.11 | 123.67 ± 24.63 |
| Visit 2 Day 1 (03:00) | 108.88 ± 7.12 | 105.00 ± 6.89 | 112.50 ± 9.29 | 111.22 ± 7.87 |
| Visit 2 Day 1 (05:00) | 115.50 ± 5.61 | 115.00 ± 8.50 | 120.88 ± 7.94 | 113.00 ± 13.32 |
| Visit 2 Day 1 (08:00) | 118.50 ± 9.06 | 113.88 ± 6.75 | 115.63 ± 5.83 | 114.89 ± 10.61 |
| Visit 2 Day 2 | 117.75 ± 9.29 | 114.13 ± 5.77 | 120.88 ± 8.46 | 119.00 ± 10.02 |
| Follow-up | 121.38 ± 8.93 | 115.63 ± 11.03 | 119.38 ± 10.21 | 122.11 ± 12.24 |
Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.
| mmHg | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Screening | 68.63 ± 5.21 | 69.75 ± 8.51 | 72.25 ± 8.01 | 73.56 ± 11.75 |
| Visit 2 Day 1 (-00:15) | 69.63 ± 3.74 | 65.88 ± 6.42 | 75.38 ± 2.77 | 69.56 ± 9.06 |
| Visit 2 Day 1 (03:00) | 69.00 ± 6.89 | 64.38 ± 7.37 | 72.63 ± 5.71 | 65.56 ± 11.20 |
| Visit 2 Day 1 (05:00) | 65.63 ± 5.88 | 62.38 ± 5.04 | 72.25 ± 7.15 | 67.00 ± 11.16 |
| Visit 2 Day 1 (08:00) | 69.00 ± 7.29 | 64.50 ± 3.89 | 70.25 ± 6.36 | 66.22 ± 9.59 |
| Visit 2 Day 2 | 71.50 ± 10.23 | 69.38 ± 4.50 | 74.25 ± 5.47 | 71.11 ± 8.15 |
| Follow-up | 68.25 ± 4.53 | 70.25 ± 7.81 | 71.00 ± 8.07 | 70.11 ± 7.99 |
Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest. There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.
| bpm | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Screening | 59.50 ± 5.21 | 66.50 ± 9.38 | 62.00 ± 11.24 | 63.22 ± 12.88 |
| Visit 2 Day 1 (-00:15) | 55.25 ± 5.44 | 52.00 ± 8.60 | 56.38 ± 5.58 | 54.44 ± 11.34 |
| Visit 2 Day 1 03:00) | 56.25 ± 5.50 | 53.13 ± 11.01 | 53.75 ± 4.95 | 50.33 ± 6.60 |
| Visit 2 Day 1 (05:00) | 65.38 ± 4.00 | 65.25 ± 9.66 | 66.00 ± 11.60 | 61.44 ± 8.92 |
| Visit 2 Day 1 (08:00) | 60.25 ± 6.82 | 59.00 ± 5.83 | 56.75 ± 7.21 | 55.67 ± 7.23 |
| Visit 2 Day 2 | 59.38 ± 9.53 | 57.63 ± 8.91 | 61.75 ± 13.48 | 61.22 ± 11.31 |
| Follow-up | 66.25 ± 9.04 | 67.88 ± 12.91 | 69.25 ± 16.26 | 67.44 ± 14.47 |
The following safety laboratory parameters were assessed: Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.
| Clinically relevant changes | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Safety Laboratory Measurements | 0 | 0 | 0 | 0 |
An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment
| Adverse events | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| No. of TEAEs | 8 | 8 | 16 | 2 |
| No. of subject-unique TEAEs | 8 | 7 | 16 | 2 |
| Subject-unique related TEAEs | 7 | 4 | 14 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF
| ng/mL | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Plasma PK Characteristics: C0 | 34200 ± 10300 | 78300 ± 12600 | 99000 ± 23100 | — |
Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF
| ng/mL | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 24600 ± 6480 | 52200 ± 8530 | 70100 ± 13100 | — |
| 5-Formyl-THF | 443 ± 432 | 609 ± 240 | 374 ± 83.2 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
| h*ng/mL | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 10900 ± 1680 | 19700 ± 1990 | 31100 ± 3210 | — |
| THF | 31800 ± 3780 | 53100 ± 10000 | 90100 ± 17500 | — |
| 5-Methyl-THF | 23400 ± 4470 | 38500 ± 6380 | 47400 ± 7540 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.
| (h*ng/mL)/mg | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 29.2 ± 5.27 | 29.8 ± 2.74 | 32.9 ± 4.93 | — |
| THF | 85.0 ± 11.8 | 80.1 ± 14.0 | 95.0 ± 19.2 | — |
| 5-Methyl-THF | 62.7 ± 12.5 | 58.3 ± 9.87 | 49.9 ± 7.91 | — |
| 5-Formyl-THF | 2.33 ± 1.97 | 1.24 ± 1.22 | 0.343 ± 0.580 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.
| hour | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 4.38 ± 1.95 | 5.37 ± 1.30 | 6.75 ± 2.31 | — |
| THF | 7.01 ± 1.52 | 8.01 ± 0.0178 | 8.75 ± 2.12 | — |
| 5-Methyl-THF | 24.0 ± 0.0339 | 24.0 ± 0.0980 | 23.8 ± 0.135 | — |
| 5-Formyl-THF | 3.41 ± 2.94 | 3.00 ± 2.92 | 1.40 ± 2.67 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:
| hour | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 0.989 ± 0.936 | 1.87 ± 0.634 | 2.03 ± 0.780 | — |
| THF | 1.35 ± 0.211 | 1.51 ± 0.267 | 1.59 ± 0.370 | — |
| 5-Methyl-THF | 5.54 ± 0.714 | 5.66 ± 0.644 | 5.84 ± 0.634 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.
| L/h | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 38.6 ± 1.84 | 35.5 ± 3.05 | 30.6 ± 5.14 | — |
| THF | 11.6 ± 1.47 | 12.6 ± 2.58 | 10.7 ± 2.37 | — |
| 5-Methyl-THF | 15.6 ± 3.11 | 16.5 ± 2.63 | 19.1 ± 3.49 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
| litre | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| MTHF | 18.1 ± 9.38 | 20.4 ± 6.10 | 18.5 ± 6.07 | — |
| THF | 21.8 ± 3.30 | 24.9 ± 4.17 | 21.6 ± 4.43 | — |
| 5-Methyl-THF | 138 ± 28.4 | 153 ± 27.4 | 181 ± 27.9 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
| ng/mL | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| THF | 16400 ± 3610 | 29600 ± 3970 | 44400 ± 6090 | — |
| 5-Methyl-THF | 2490 ± 450 | 3950 ± 755 | 4740 ± 484 | — |
| 5-Formyl-THF | 642 ± 474 | 619 ± 257 | 386 ± 75.3 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted
| hour | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| THF | 0.267 ± 0.334 | 0.123 ± 0.0786 | 0.300 ± 0.179 | — |
| 5-Methyl-THF | 3.12 ± 0.835 | 3.50 ± 1.07 | 3.63 ± 0.519 | — |
| 5-Formyl-THF | 0.0778 ± 0.0255 | 0.102 ± 0.0601 | 0.142 ± 0.145 | — |
Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.
| ng/mL/mg | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF | 1.73 ± 1.33 | 0.934 ± 0.379 | 0.407 ± 0.0826 | — |
An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment
| Subjects | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| Subjects with at least one TEAE | 6 | 5 | 8 | 1 |
| Subjects with at least one related TEAE | 5 | 3 | 8 | 0 |
| Withdrawals due to TEAE | 0 | 0 | 0 | 0 |
Collected over Adverse event data was collected from start of IMP administration to last subject last visit, thus during a period of little less than 2 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg/m2 of Modufolin® | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| 350 mg/m2 of Modufolin® | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| 500 mg/m2 of Modufolin® | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Event | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/8 | 2/8 | 4/8 | 0/9 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 3/8 | 0/9 |
| DysgeusiaNervous system disorders | 0/8 | 0/8 | 2/8 | 0/9 |
| ParaesthesiaNervous system disorders | 1/8 | 0/8 | 2/8 | 0/9 |
| Paraesthesia oralNervous system disorders | 2/8 | 1/8 | 0/8 | 0/9 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 1/8 | 0/9 |
| HeadacheNervous system disorders | 1/8 | 1/8 | 1/8 | 1/9 |
| HypoaesthesiaNervous system disorders | 0/8 | 1/8 | 0/8 | 0/9 |
| Hypoaesthesia oralNervous system disorders | 0/8 | 0/8 | 1/8 | 0/9 |
| ChillsGeneral disorders | 1/8 | 0/8 | 0/8 | 0/9 |
| Age, Categorical(Participants) | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 9 | 33 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 8 | 8 | 8 | 9 | 33 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 2 |
| Not Hispanic or Latino | 7 | 8 | 7 | 9 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 200 mg/m2 of Modufolin® | 350 mg/m2 of Modufolin® | 500 mg/m2 of Modufolin® | Placebo | Total |
|---|---|---|---|---|---|
| Sweden | 8 | 8 | 8 | 9 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Aug 2017, 1 month.
Results were first posted in Mar 2020, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid
Isofol Medical AB